Advertisement

Advertisement

NRSN Stock Latest News

NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3

Company AnnouncementsNeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3

NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint

PremiumThe Fly

NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint

11d ago

NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial

PremiumCompany Announcements

NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial

15d ago

NeuroSense Secures South Korean Patent for ALS Drug Candidate PrimeC

PremiumCompany Announcements

NeuroSense Secures South Korean Patent for ALS Drug Candidate PrimeC

29d ago

NeuroSense granted South Korean patent covering PrimeC composition for ALS

PremiumThe Fly

NeuroSense granted South Korean patent covering PrimeC composition for ALS

29d ago

NeuroSense Therapeutics Wins Key Japanese Patent for ALS Drug PrimeC

PremiumCompany AnnouncementsNeuroSense Therapeutics Wins Key Japanese Patent for ALS Drug PrimeC

1M ago

NeuroSense granted Japanese patent for PrimeC novel composition in ALS

The Fly

NeuroSense granted Japanese patent for PrimeC novel composition in ALS

1M ago

NeuroSense Therapeutics Advances Canadian Regulatory Talks on ALS Drug PrimeC

Company Announcements

NeuroSense Therapeutics Advances Canadian Regulatory Talks on ALS Drug PrimeC

1M ago

NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price

PremiumCompany Announcements

NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price

2M ago

NeuroSense announces departure of Chief Medical Officer

PremiumThe Fly

NeuroSense announces departure of Chief Medical Officer

2M ago

NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones

PremiumCompany Announcements

NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones

3M ago

NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC

PremiumCompany Announcements

NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC

3M ago

NeuroSense granted Brazilian patent covering PrimeC composition

PremiumThe FlyNeuroSense granted Brazilian patent covering PrimeC composition

3M ago

NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status

Company Announcements

NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status

3M ago

NeuroSense Therapeutics Posts 2025 Results as PrimeC Advances Toward Phase 3 ALS Trial

Company Announcements

NeuroSense Therapeutics Posts 2025 Results as PrimeC Advances Toward Phase 3 ALS Trial

3M ago

NeuroSense Reschedules Health Canada Meeting as PrimeC Data Package Strengthens

PremiumCompany Announcements

NeuroSense Reschedules Health Canada Meeting as PrimeC Data Package Strengthens

4M ago

Neurosense Therapeutics Ltd. (NRSN) Q4 Earnings Cheat Sheet

PremiumPre-Earnings

Neurosense Therapeutics Ltd. (NRSN) Q4 Earnings Cheat Sheet

4M ago

NeuroSense’s ALS Drug PrimeC Shows Strong Phase 2b Results in JAMA Neurology

PremiumCompany Announcements

NeuroSense’s ALS Drug PrimeC Shows Strong Phase 2b Results in JAMA Neurology

4M ago

NeuroSense Shareholders Approve Increase in Registered Share Capital

PremiumCompany Announcements

NeuroSense Shareholders Approve Increase in Registered Share Capital

4M ago

NeuroSense initiated with a Buy at Roth Capital

PremiumThe FlyNeuroSense initiated with a Buy at Roth Capital

4M ago

NeuroSense Reports 65% Lower Mortality Risk and 14-Month Survival Gain for PrimeC in ALS Trial

Company Announcements

NeuroSense Reports 65% Lower Mortality Risk and 14-Month Survival Gain for PrimeC in ALS Trial

5M ago

NeuroSense reports additional long-term survival data from PARADIGM 2b trial

The Fly

NeuroSense reports additional long-term survival data from PARADIGM 2b trial

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >